Shionogi & Co., Ltd. and its group company Shionogi Pharma Co., Ltd. today announced that Shionogi Pharma’s Kanegasaki Plant has obtained the international certification “BSI Kitemark™ for Minimized Risk of AMR” for both the active pharmaceutical ingredient (API) and formulation manufacturing processes of cefiderocol, a treatment for infections caused by multidrug-resistant Gram-negative bacteria.
Shionogi Press Release